topotecan + docetaxel

Topotecan + docetaxel is a combination regimen of two chemotherapeutic agents used primarily in the treatment of various solid tumors, including lung cancer. Topotecan is a topoisomerase I inhibitor that interferes with DNA replication by stabilizing the cleavable complex between DNA and topoisomerase I, leading to DNA damage and cell death. Docetaxel is a taxane-class antineoplastic agent that promotes microtubule assembly while inhibiting their disassembly, resulting in cell cycle arrest and apoptosis. The combination has been studied for synergistic effects against tumor cells but is associated with significant hematologic toxicity, particularly neutropenia[1][2][8]. Clinical trials have evaluated this regimen mainly in patients with relapsed or refractory small cell lung cancer and other advanced solid tumors[3][4].

Brand names

HycamtinTaxotere

Other names

topotecan and docetaxeldocetaxel and topotecan